[
  {
    "study_id": "NCT04567890",
    "title": "Efficacy and Safety of Drug X in Patients with Type 2 Diabetes",
    "brief_title": "Drug X for T2DM Study",
    "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Drug X in Adult Patients with Type 2 Diabetes Mellitus",
    "study_type": "Interventional",
    "phase": "Phase 3",
    "allocation": "Randomized",
    "intervention_model": "Parallel Assignment",
    "masking": "Double Blind",
    "primary_purpose": "Treatment",
    "enrollment": {
      "count": 1200,
      "type": "Actual"
    },
    "conditions": [
      "Type 2 Diabetes Mellitus",
      "Hyperglycemia",
      "Metabolic Disorder"
    ],
    "interventions": [
      {
        "type": "Drug",
        "name": "Drug X",
        "description": "Drug X 10mg tablet taken orally once daily",
        "arm_group_label": "Drug X Treatment",
        "other_names": ["DrugX", "Compound-123"]
      },
      {
        "type": "Drug",
        "name": "Placebo",
        "description": "Matching placebo tablet taken orally once daily",
        "arm_group_label": "Placebo Control"
      }
    ],
    "primary_outcomes": [
      {
        "measure": "Change in HbA1c from baseline to week 24",
        "time_frame": "24 weeks",
        "description": "Mean change in glycated hemoglobin (HbA1c) levels"
      }
    ],
    "secondary_outcomes": [
      {
        "measure": "Proportion of subjects achieving HbA1c < 7%",
        "time_frame": "24 weeks"
      },
      {
        "measure": "Change in fasting plasma glucose",
        "time_frame": "24 weeks"
      },
      {
        "measure": "Change in body weight",
        "time_frame": "24 weeks"
      }
    ],
    "eligibility": {
      "gender": "All",
      "minimum_age": "18 Years",
      "maximum_age": "75 Years",
      "healthy_volunteers": false,
      "criteria": "Inclusion: Adults with T2DM, HbA1c 7.0-10.5%, stable metformin therapy. Exclusion: Type 1 diabetes, severe renal impairment, pregnancy."
    },
    "overall_status": "Completed",
    "start_date": "2023-01-15",
    "completion_date": "2024-02-28",
    "location": {
      "facility": "Multi-center International Study",
      "city": "Various",
      "country": "Multiple Countries"
    },
    "sponsors": {
      "lead_sponsor": "PharmaCorp Inc.",
      "collaborators": ["Academic Research Institute", "Clinical Research Organization"]
    },
    "study_results": {
      "primary_outcome_results": {
        "baseline_hba1c": 8.2,
        "week_24_hba1c": 7.1,
        "mean_change": -1.1,
        "p_value": "<0.001",
        "confidence_interval": "95% CI: -1.3 to -0.9"
      },
      "adverse_events": [
        {
          "event": "Nausea",
          "drug_x_group": "12%",
          "placebo_group": "5%"
        },
        {
          "event": "Diarrhea", 
          "drug_x_group": "8%",
          "placebo_group": "3%"
        },
        {
          "event": "Hypoglycemia",
          "drug_x_group": "3%",
          "placebo_group": "1%"
        }
      ]
    }
  },
  {
    "study_id": "NCT04789123",
    "title": "Cardiovascular Safety Study of Aspirin in High-Risk Patients",
    "brief_title": "Aspirin CVD Prevention Study",
    "official_title": "Long-term Cardiovascular Safety and Efficacy of Low-Dose Aspirin in High-Risk Primary Prevention Patients: A Randomized Controlled Trial",
    "study_type": "Interventional",
    "phase": "Phase 4",
    "allocation": "Randomized",
    "intervention_model": "Parallel Assignment", 
    "masking": "Double Blind",
    "primary_purpose": "Prevention",
    "enrollment": {
      "count": 15000,
      "type": "Actual"
    },
    "conditions": [
      "Cardiovascular Disease",
      "Primary Prevention",
      "High Cardiovascular Risk"
    ],
    "interventions": [
      {
        "type": "Drug",
        "name": "Aspirin",
        "description": "Aspirin 81mg enteric-coated tablet taken orally once daily",
        "arm_group_label": "Aspirin Treatment",
        "other_names": ["Acetylsalicylic Acid", "ASA"]
      },
      {
        "type": "Drug", 
        "name": "Placebo",
        "description": "Matching placebo tablet taken orally once daily",
        "arm_group_label": "Placebo Control"
      }
    ],
    "primary_outcomes": [
      {
        "measure": "Major Cardiovascular Events (MACE)",
        "time_frame": "5 years",
        "description": "Composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke"
      }
    ],
    "secondary_outcomes": [
      {
        "measure": "All-cause mortality",
        "time_frame": "5 years"
      },
      {
        "measure": "Major bleeding events",
        "time_frame": "5 years"
      },
      {
        "measure": "Gastrointestinal bleeding",
        "time_frame": "5 years"
      }
    ],
    "eligibility": {
      "gender": "All",
      "minimum_age": "50 Years",
      "maximum_age": "80 Years", 
      "healthy_volunteers": false,
      "criteria": "Inclusion: Age 50-80, elevated CVD risk score, no history of CVD. Exclusion: Prior CVD events, bleeding disorders, aspirin allergy."
    },
    "overall_status": "Active, not recruiting",
    "start_date": "2020-03-10",
    "completion_date": "2025-12-31",
    "location": {
      "facility": "International Multi-center Study",
      "city": "Various",
      "country": "US, UK, Canada, Australia"
    },
    "sponsors": {
      "lead_sponsor": "Cardiovascular Research Foundation",
      "collaborators": ["National Heart Institute", "Global Health Organization"]
    },
    "interim_results": {
      "interim_analysis_date": "2024-06-30",
      "mace_events": {
        "aspirin_group": "8.2%",
        "placebo_group": "10.1%",
        "hazard_ratio": 0.81,
        "confidence_interval": "95% CI: 0.73-0.91",
        "p_value": "0.0003"
      },
      "bleeding_events": {
        "major_bleeding_aspirin": "2.3%",
        "major_bleeding_placebo": "1.1%",
        "gi_bleeding_aspirin": "1.8%",
        "gi_bleeding_placebo": "0.7%"
      }
    }
  }
]